PT  - JOURNAL ARTICLE
AU  - Xing, Quan-sheng
AU  - Li, Guo-ju
AU  - Xing, Yu-han
AU  - Chen, Ting
AU  - Li, Wen-jie
AU  - Ni, Wei
AU  - Deng, Kai
AU  - Gao, Ru-qin
AU  - Chen, Chang-zheng
AU  - Gao, Yang
AU  - Li, Qiang
AU  - Yu, Gui-ling
AU  - Tong, Jian-ning
AU  - Li, Wei
AU  - Hao, Gui-liang
AU  - Sun, Yue
AU  - Zhang, Ai
AU  - Wu, Qin
AU  - Ma, Guang-ren
AU  - Li, Zi-pu
AU  - Pan, Si-lin
TI  - Precautions are Needed for COVID-19 Patients with Coinfection of Common Respiratory Pathogens
AID  - 10.1101/2020.02.29.20027698
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.29.20027698
4099  - http://medrxiv.org/content/early/2020/03/03/2020.02.29.20027698.short
4100  - http://medrxiv.org/content/early/2020/03/03/2020.02.29.20027698.full
AB  - Background In our clinical practice, we found a large proportion of patients diagnosed with Coronavirus Disease 2019 (COVID-19) had coinfections with other seasonal respiratory pathogens in Qingdao, northeast China, which differed greatly from earlier cases reported in the epidemic center, Wuhan, central China.Objectives To clarify the pattern of coinfection with other common respiratory pathogens in COVID-19 patients in Qingdao and Wuhan; to explore the possible reasons underlying the between-region difference.Methods We conducted a double-center study and recruited 64 patients with laboratory- confirmed severe acute respiratory coronavirus 2 (SARS-CoV-2) infection from three hospitals in Qingdao and one hospital in Wuhan from January 17 to February 16, 2020. Indirect immunofluorescence (IIFA) was performed to detect the specific IgM antibody against common respiratory pathogens in collected acute phase serum.Results Of the 68 patients with SARS-CoV-2 infection, 30 (44.12%) were from Qingdao. The median age of Qingdao and Wuhan patients were 50 years and 31 years, respectively, and the majority of patients were female in Qingdao (60.00%) and Wuhan (55.26%). Among COVID-19 patients in Qingdao, 24 of them had IgM antibodies against at least one respiratory pathogen, and the overall positive rate was 80.00%, whereas only one (2.60%) of the patients in Wuhan had positive results for serum IgM antibody detection (P<0.0001). The most common respiratory pathogens detected in Qingdao COVID-19 patients were IFV-A (60.00%) and IFV-B (53.30%), followed by MP (23.30%) and LP (20.00%). Only 13.33% of healthy control group (n=4) had specific-IgM antibody (against IFV-B) detected in the serum, a figure significantly lower than that in COVID-19 patients in Qingdao (P<0.0001). None of the healthy control had combined infection. The most common respiratory pathogens detected in COVID-19 patients were IFV-A and IFV-B (23.33%); while the pattern for coinfection in patients with community-acquired pneumonia was quite different, with a coinfection rate of only 8.96%.Interpretation With the ongoing outbreak of COVID-19, patients within and beyond the epidemic area behaved differently. More attention should be paid for the coinfection of other respiratory pathogens in patients with COVID-19. We highly recommend adding SARS-CoV-2 to the routine testing assay in capable hospitals to prevent misdetection of the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by The National Natural Science Foundation of China (NSFC) [Grant number 81770315]; and Distinguished Taishan Scholars (2019).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe complete dataset is included in this manuscript